The Front Room — a clinical regulatory commons
RSS
← Back to feed

Tauklarify cleared as tau PET imaging agent for Alzheimer's disease

Sponsor
Lantheus Holdings, Inc. $LNTH
Drug
Tauklarify · florquinitau F 18
Indication
Alzheimer's disease imaging
More on Lantheus Holdings, Inc. ↗ Google News

FDA approves Tauklarify (florquinitau F 18 injection), an F18-labeled tau PET imaging agent for use in Alzheimer's disease.

What this means

Tauklarify is a radioactive dye that sticks to tau protein tangles in the brain, allowing doctors to see them on a PET scan. The FDA has cleared it for use in evaluating adult patients with cognitive impairment who are being assessed for Alzheimer's disease. This provides a new tool to help confirm the presence of Alzheimer's pathology, which may aid in diagnosis and patient management.

Read original at drugs.com ↗
Topic Alzheimer's disease diagnostics